AC Immune SA (ACIU) - Form 20-F Summary
Business Context and Reporting Period
Company: AC Immune SA
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: AC Immune is a clinical-stage biopharmaceutical company focused on developing precision medicine for neurodegenerative diseases (NDD), specifically Alzheimer's disease (AD), Parkinson's disease (PD), and other protein misfolding disorders. The company utilizes two proprietary technology platforms: SupraAntigen (biologics/immunotherapies) and Morphomer (small molecules).
Key Pipeline Assets:
- ACI-24.060: Anti-Abeta active immunotherapy for AD and Down Syndrome (DS).
- ACI-35.030: Anti-pTau active immunotherapy for preclinical AD (partnered with Janssen).
- ACI-7104.056: Anti-a-syn active immunotherapy for PD.
- PI-2620: Tau-PET diagnostic tracer (partnered with LMI).
- ACI-12589/ACI-15916: Alpha-synuclein PET tracers.
- ACI-19626: TDP-43 PET tracer.
Key Financial Metrics (Year Ended Dec 31, 2024)
| Metric | 2024 (CHF) | 2023 (CHF) |
|---|---|---|
| Total Revenue | 27.3 million | 14.8 million |
| Net Loss | (50.9) million | (54.2) million |
| Accumulated Losses | (368.2) million | (316.2) million |
| Research & Development Expenses | 62.6 million | 54.6 million |
| General & Administrative Expenses | 17.3 million | 15.3 million |
| Cash & Cash Equivalents | 36.3 million | 78.5 million |
| Short-term Financial Assets | 129.2 million | 24.6 million |
| Total Liquidity | 165.5 million | 103.0 million |
| Net Cash from Operating Activities | 65.8 million | (60.4) million |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased by 84% (CHF 12.5 million) primarily driven by a CHF 24.6 million milestone payment from Janssen for the rapid prescreening in the Phase 2b ReTain trial and CHF 2.7 million in revenue recognized from development services under the new Takeda agreement.
- Liquidity Position: Total liquidity increased significantly to CHF 165.5 million, largely due to a CHF 92.3 million upfront payment from Takeda in May 2024 and the Janssen milestone. This was partially offset by increased R&D spending.
- Operating Cash Flow: Shifted from a net cash outflow of CHF 60.4 million in 2023 to a net cash inflow of CHF 65.8 million in 2024, driven by the timing of deferred contract revenue recognition and milestone receipts.
- Collaboration Changes:
- Takeda: Entered a new exclusive option and license agreement for ACI-24.060 in May 2024.
- Genentech: Collaboration agreements for crenezumab and semorinemab terminated in April 2024; AC Immune regained global rights to these assets in February 2025.
Guidance, Outlook, and Risks
Outlook: Management believes current capital resources (CHF 165.5 million) are sufficient to fund projected operating requirements into Q1 2027, assuming no additional milestone payments are received. The company expects to continue incurring losses as it advances clinical programs.
Key Risks:
- Clinical Development: High uncertainty regarding the success of clinical trials for product candidates (ACI-24.060, ACI-35.030, ACI-7104.056). Failure to demonstrate safety or efficacy could halt development.
- Regulatory Approval: No products are currently approved for sale. Regulatory approval is not guaranteed and timelines are uncertain.
- Capital Requirements: The company may need to raise additional capital to fund operations beyond Q1 2027 or to accelerate development, which could result in shareholder dilution.
- Collaboration Dependence: Reliance on partners (Janssen, Takeda, LMI) for development and commercialization of key assets. Termination of these agreements could materially harm the business.
- Intellectual Property: Risks related to patent expiration, infringement claims, and the ability to maintain exclusivity.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the CHF 165.5 million liquidity position against the projected burn rate into Q1 2027, considering potential inflation or accelerated clinical timelines.
- Takeda Agreement Terms: Review the specific conditions for the option exercise fee and the recognition of the CHF 80.7 million deferred revenue allocated to the license option.
- Janssen Milestone Sustainability: Assess the likelihood of future milestone payments from Janssen given the progression of the ReTain trial.
- Regained Assets Strategy: Evaluate the company's plan and funding requirements for the re-acquired assets (crenezumab and semorinemab) following the Genentech termination.
- IPR&D Asset Valuation: Review the assumptions used in the valuation of the CHF 50.4 million in-process research and development (IPR&D) asset, particularly regarding the probability of success for the Parkinson's disease candidate.